Journal: PeerJ

Article Title: ERO1A as a novel biomarker for risk stratification and immunotherapeutic guidance in early-stage lung adenocarcinoma

doi: 10.7717/peerj.21347

Figure Lengend Snippet: (A) Pan-cancer analysis of ERO1A expression between tumor and normal (or primary and metastatic) tissues from the TIMER database. (B) ERO1A expression in LUAD and normal tissues based on TCGA and GTEx data (GEPIA). *** P < 0.001; unpaired Student’s t-test. (C) Representative immunohistochemical (IHC) staining images of ERO1A in normal and LUAD tissues from the Human Protein Atlas (HPA) database. (D) ERO1A protein expression in normal lung tissues and LUAD tissues based on the HPA database. (E, F) Survival analysis (GEPIA) of ERO1A expression in TCGA-LUAD: (E) overall survival (OS, P < 0.001), (F) disease-free survival (DFS, P = 0.018). (G) ERO1A mRNA expression in TCGA-esLUAD tumors ( n = 233) vs normal tissues ( n = 32). *** P < 0.001; unpaired t-test. (H) Receiver operating characteristic (ROC) curve evaluating the performance of ERO1A expression in discriminating tumor from normal tissue (AUC = 0.988). (I, J) Kaplan-Meier survival analysis in TCGA-esLUAD based on ERO1A expression: (I) OS ( P = 0.007), (J) relapse-free survival (RFS, P = 0.004); log-rank test. (K, L) Time-dependent ROC (tROC) curves predicting (K) OS and (L) RFS at 1, 2, and 3 years in the TCGA-esLUAD cohort. (M) Kaplan-Meier analysis of OS in the GSE72094 esLUAD cohort stratified by ERO1A expression. *** P < 0.001; log-rank test. (N) ERO1A expression between alive ( n = 144) and deceased ( n = 77) patients in the GSE72094 esLUAD cohort. *** P < 0.001; unpaired t-test. (O) Representative images of ERO1A IHC staining in our institutional cohort of esLUAD tissue sections ( n = 90); right panel shows a magnified view of the region indicated by the box. Scale bar: 200 μm. (P) DFS analysis based on ERO1A high/low expression groups defined by IHC H-Score from our cohort. P = 0.002, log-rank test. (Q) Comparison of ERO1A H-Score between patients with ( n = 8) and without ( n = 82) DFS events. P = 0.008; Mann-Whitney U test. Abbreviations: esLUAD, early-stage lung adenocarcinoma; TIMER, tumor immune estimation resource; LUAD, lung adenocarcinoma; TCGA, the cancer genome atlas; GTEx, genotype-tissue expression; GEPIA, gene expression profiling interactive analysis; IHC, immunohistochemistry; HPA, human protein atlas; OS, overall survival; DFS, disease-free survival; ROC, receiver operating characteristic; AUC, area under the curve; RFS, relapse-free survival; tROC, time-dependent receiver operating characteristic; H-score, histochemistry score. *** P < 0.001; ** P < 0.01; * P < 0.05; ns, not significant.

Article Snippet: Immunohistochemistry (IHC) data from the Human Protein Atlas further revealed that normal lung parenchyma was almost devoid of ERO1A protein, whereas virtually all LUAD specimens exhibited positive staining with intensities ranging from weak to strong, resulting in a significantly higher overall protein level than normal controls ( , ; with quantitative data shown in ).

Techniques: Expressing, Immunohistochemical staining, Immunohistochemistry, Comparison, MANN-WHITNEY, Gene Expression

Journal: International Journal of Nanomedicine

Article Title: Transferrin-Functionalized Conjugated Polymer Nanoparticles for Enhanced Photodynamic Therapy of Glioblastoma

doi: 10.2147/IJN.S592688

Figure Lengend Snippet: Integrated in silico and experimental analysis of transferrin receptor 1 (TfR1 / TFRC) expression in gliomas and representative cell lines. Box-plot summary of TFRC mRNA expression obtained from GEPIA (Gene Expression Profiling Interactive Analysis) based on tumor and normal samples from the TCGA and the GTEx databases (accessed March 2025). ( A ) Comparison of TFRC expression in high-grade gliomas (GBM) vs. low-grade glioma (LGG) (n indicated on each plot). ( B ) TFRC expression stratified by canonical GBM molecular subtype (classical, mesenchymal, neural, proneural). Boxes represent the interquartile range, horizontal lines the median, whiskers extend to 1.5×IQR, and individual data points are overlaid. Brackets with asterisks denote statistically significant pairwise differences (see Methods for statistical test). ( C ) TfR1 expression levels in GBM cell lines and HEK293 (non-tumor control). Data taken and adapted from the Human Protein Atlas. ( D ) Representative flow-cytometry histograms of surface TfR1 staining in U87MG, T98G, MO59K and HEK293 cells. Traces correspond to unstained control (red), secondary-only control (anti-mouse IgG–AF647; Orange) and specific anti-CD71 primary staining followed by anti-mouse-AF647 secondary (blue). The horizontal bracket on each histogram indicates the gate used to define TfR1-positive events. ( E ) gMFI of the CD71 signal (mean ± SD; n = biological replicates indicated in Methods), and ( F ) percentage of TfR1-positive cells. Data were normalized to appropriate controls. Statistical comparisons were performed as described in Methods (* p < 0.05 ).

Article Snippet: In addition, representative immunohistochemistry (IHC) images illustrating TfR1 protein expression in human brain tissues were retrieved from the Human Protein Atlas (HPA) database ( https://www.proteinatlas.org ), an open-access resource providing antibody-based protein expression profiles across normal and cancer tissues.

Techniques: In Silico, Expressing, Gene Expression, Comparison, Control, Flow Cytometry, Staining